CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 294 enrolled
Drug / intervention
Varenicline tartrate +3 moredrug
Likely dose
Varenicline tartrate 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00701896
NCT00701896N/ACompleted
CompareCT.gov

Smoking Cessation and the Natural History of HIV-Associated Emphysema

Philip Diaz·interventional·Posted Jun 19, 2008·Updated Jan 15, 2021

In Brief

A clinical study evaluating Varenicline tartrate, Nicotine Replacement Therapy, and 2 other interventions for Smoking and HIV Infections. Completed, enrolled 294 participants across 1 site.

Detailed Summary

People that are infected with HIV appear to be especially susceptible to the adverse effects of cigarette smoking. The purpose of this study is to determine if quitting smoking by using a specialized smoking cessation treatment can prevent one from developing accelerated lung damage, particularly emphysema.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking, HIV Infections
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 19, 2008
Enrollment StartOct 3, 2008
Primary CompletionApr 20, 2013
Study CompletionJun 20, 2013
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 18.0 years ago

Interventions

Varenicline tartratedrug

1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.

Nicotine Replacement Therapydrug

Nicotine gum and nicotine patch

Biological Controlother

No treatment intervention only information and procedures.

Motivational Interviewbehavioral

60 minute one-on-one Interview